Tango Therapeutics, Inc.
Clinical trials sponsored by Tango Therapeutics, Inc., explained in plain language.
A clinical-stage biotechnology company developing targeted cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for hard-to-treat cancers: experimental combo targets STK11 mutation Results expected Sep 2026 (estimated)
- New drug targets Hard-to-Treat cancers with missing gene Results expected Mar 2027 (estimated) May already have reported ↗
- New hope for hard-to-treat cancers: targeted combo trial opens Results expected Jun 2027 (estimated)
- New pill targets Hard-to-Treat cancers with missing gene Results expected Jun 2027 (estimated)
-
New pill targets Hard-to-Treat cancers with missing gene
Disease control Recruiting nowThis study tests an experimental drug called TNG462 for people with advanced solid tumors that have a specific genetic deletion (MTAP). The drug is taken by mouth and aims to slow or stop tumor growth. The trial has two parts: first, finding the safest dose, and then testing that…
Phase 1/2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for hard-to-treat cancers: targeted combo trial opens
Disease control Recruiting nowThis study tests a new oral drug, TNG462, combined with other treatments for people with pancreatic or non-small cell lung cancer that has lost the MTAP gene and, in some cases, has a RAS mutation. The trial has two phases: first to find the safest dose, then to see how well the …
Phase 1/2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug targets Hard-to-Treat cancers with missing gene
Disease control Recruiting nowThis study tests a new drug called TNG456, alone or with another drug (abemaciclib), in people with advanced cancers that have lost a gene called MTAP. The trial has two parts: first finding a safe dose, then testing how well it shrinks tumors. Up to 191 adults with lung cancer, …
Phase 1/2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC